Therefore, blocking the inflammasome–IL-1α/IL-1R signaling cascade (41) may show a great therapeutic potential benefits in kidney injury, especially in DKD, and may help to attenuate disease progression to ESRD. This evidence concerns the gene IL1A and diabetic kidney disease.